NCT06849518Recruiting
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
Source: ClinicalTrials.gov · Last updated 28 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 24 Feb 2025
- Start date
- 11 Feb 2025
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Ballad Health
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT06849518
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 11 Feb 2025 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No anti-PD-1/L1 monoclonal antibody treatment.
- Planned primary radiation therapy.
Other illness
- Small-cell lung cancer histology.
Who the study is looking for
- All patients with a diagnosis of stage IV or inoperable stage IIIB NSCLC without planned primary radiation therapy undergoing anti-PD-1/L1 based ICI treatment.
- Chemo-immune or dual anti-PD-1/L1 with anti-CTLA-4 based regimens are eligible as long as receiving an anti-PD-1/L1 monoclonal antibody.
- A documented informed consent will be obtained prior to inclusion in the study. All discussions with patients will be held in strictest confidence and out of earshot of the general public. Patients will be fully informed that their participation in the study is voluntary. Patients may decline to be part of the study. Their decision to participate in the study will not affect the care they receive.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ballad Health Cancer Care Coordinator of this site? Confirm its status | Kingsport | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.